valcyte怎么样？

Valaciclovir hydrochloride tablets () are a prescription antiviral drug. Indications: Treatment of cytomegalovirus (CMV) retinitis in people with immunodeficiency syndrome (AIDS). When the CMV virus infects the eye, it is called CMV retinitis. If CMV retinitis is not treated, blindness may result. To prevent CMV disease in people who have received a kidney, heart, or kidney-pancreas transplant and are at high risk for CMV disease.

August 11, 2010 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced yesterday that the U.S. Food and Drug Administration (FDA) has approved the increased use of valamciclovir hydrochloride tablets (valcyte) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

The supplemental approval is based on data that longer-term prophylactic treatment with valamciclovir hydrochloride tablets (valcyte) reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) one year after receiving a kidney transplant) (p <0.0001).1.2 The overall safety profile of valcyte does not change when prophylaxis is extended in high-risk renal transplant patients.

"Among the different risks that people face after kidney transplantation, CMV is one that can be prevented through preventive treatment with valcyte," said researcher Atul Humar, MD, associate professor in the Department of Transplantation Infectious Diseases and Medicine at the University of Aberdeen. "Data now show that by increasing the duration of prophylactic treatment with valaciclovir from 100 to 200 days, we can further reduce the risk of CMV infection.